Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPAX-3: TLX101-Tx plus lomustine versus lomustine in first recurrent glioblastoma
2025-521785-10-00Phase 3Authorised
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Oct 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of 4-iodophenylalanine I-131 and lomustine in glioblastoma (GBM) (4 arms), sponsored by Telix Pharmaceuticals Limited. Primary endpoints: Dose-limiting toxicity and TEAEs, Safety and tolerability and 1 more. Planned start Oct 2025; status: authorised.
02
Drugs
4-iodophenylalanine I-131lomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2025-521785-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521785-10-00.